Comparison · NCT02679170-deaths
ALK Treatment Sub-study vs ROS1 Treatment Sub-study: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. ALK Treatment Sub-study vs ROS1 Treatment Sub-study: deaths from any cause. Trial comparisons, record NCT02679170-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02679170-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.418 | 0.322 | 0.52 | wilson | |
| Risk in group 2 | 0.5 | 0.366 | 0.634 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0824 | -0.247 | 0.086 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.835 | 0.578 | 1.21 | log | |
| Odds ratio, group 1 over group 2 | 0.717 | 0.358 | 1.43 | log | |
| Number needed to treat, for one fewer death from any cause on ALK Treatment Sub-study than on ROS1 Treatment Sub-study | 12.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | ALK Treatment Sub-study | Participants with advanced/metastatic NSCLC with confirmed ALK-positive translocation and who were treated with crizotinib in routine clinical practice retrospectively from January 2014 or prospectively during the study were included. | 38 | 91 | EG000 |
| Group 2 | ROS1 Treatment Sub-study | Participants with advanced/metastatic NSCLC with confirmed ROS1-positive translocation and who were treated with crizotinib in routine clinical practice on or after 08-Feb-2017 were included. | 25 | 50 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- From start of study treatment until end of follow-up (ALK treatment sub-study: maximum of 96.5 months and ROS1 treatment sub-study: maximum of 46.6 months)
Source ClinicalTrials.gov
Trial
- Title
- Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)
- NCT number
- NCT02679170
- Phases
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Crizotinib
- Lead sponsor
- Pfizer
- Results first posted
- 2024-08-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02679170?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02679170-deaths